



RECEIVED
APR 30 2003
TECH CENTER 1600/2900

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on April 23, 2003

Tiffany L. Bell

Tiffany Bell

PATENT

Attorney Docket No. 39780-2630P1C62

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| | | |
|--|---|---------------------------|
| In re Application |) | <u>PATENT APPLICATION</u> |
| |) | |
| Inventor(s): Avi Ashkenazi et al. |) | |
| |) | Art Unit: 1647 |
| Application No.: 10/017,191 |) | |
| |) | Examiner: To Be Assigned |
| Filed: October 24, 2001 |) | |
| |) | |
| Title: Secreted and Transmembrane Polypeptides and |) | |
| Nucleic Acids Encoding The Same |) | |
| |) | |

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

Commissioner for Patents
Washington, D.C. 20231

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy of each listed publication and U.S. and foreign patent, except for pending U.S. applications, is being submitted herewith, along with a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. §1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If form PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with MPEP §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

- ☐ This statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):
- ☐ (1) It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d)
-- OR --
- ☐ (2) It is being filed within 3 months of entry of a national stage
-- OR --
- ☒ (3) It is being filed before the mail date of the first Office Action on the merits
-- OR --
- ☐ (4) It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.
- ☐ 37 C.F.R. §1.97(c). If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in §1.491 in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, then:
- ☐ a certification as specified in §1.97(e) is provided below; **or**
- ☐ a fee of \$180.00 as set forth in §1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.
- ☐ 37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then:
- A. a certification as specified in §1.97(e) is completed below; and
- B. a petition under 37 C.F.R. §1.97(d) requesting consideration of this statement is submitted herewith; **and**
- C. a fee of \$130.00 as set forth in §1.17(i)(1) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.
- ☐ **Fee Authorization.** The Commissioner is hereby authorized to charge the above-referenced fees of \$0.00 and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. 08-1641 (Docket No. 39780-2630P1C62).

Respectfully submitted,

HELLER EHRMAN WHITE & MCAULIFFE LLP

Dated: September 21, 2002

By: Ginger R. Dreger
Ginger R. Dreger, Reg. No. 33,055

275 Middlefield Road
Menlo Park, CA 94025-3506
(650) 324-7000
Customer No. 25213


**INFORMATION DISCLOSURE
STATEMENT**

PTO-1449

ATTY. DOCKET NO.

39780-2630P1C62

SERIAL NO.

10/017,191

APPLICANT Ashkenazi et al.

FILING DATE 10/24/01

GROUP: 1647

U.S. PATENT DOCUMENTS

| EXAMINER'S INITIALS | PATENT NO. | DATE | NAME | CLASS | SUBCLASS | FILING DATE |
|------------------------|------------|------|------|-------|----------|-------------|
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

RECEIVED
APR 30 2003
TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

| EXAMINER'S INITIALS | PATENT NO. | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION | |
|------------------------|-------------|---------|---------|-------|----------|--------------------------|--------------------------|
| | | | | | | YES | NO |
| | WO 99/27096 | 6/03/99 | PCT | C12N | 15/12 | <input type="checkbox"/> | <input type="checkbox"/> |
| | | | | | | <input type="checkbox"/> | <input type="checkbox"/> |
| | | | | | | <input type="checkbox"/> | <input type="checkbox"/> |
| | | | | | | <input type="checkbox"/> | <input type="checkbox"/> |

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

| | |
|----------|--|
| | Hilliar, L. et al., "Generation and Analysis of 280,000 Human Expressed Sequence Tags", <i>Genbank</i> , Accession No. AA195615, <i>Genome. Res.</i> 6(9), pp. 807-828 (1996). |
| | Crkvenjakov, R. et al., "New Polypeptide With Epidermal Growth Factor Repeat Domains", <i>Genbank</i> , Accession No. P_AAX79501, WO 99/27096-A1, filed 23 Nov. 1998, pub. 03 Jun. 1999. |
| | Crkvenjakov, R. et al., "New Polypeptide With Epidermal Growth Factor (EGF) Repeat Domains", <i>Genbank</i> , Accession No. P_AAY18108, WO 99/27096, filed 23 Nov. 1998, pub. 03 Jun 1999. |
| EXAMINER | DATE CONSIDERED |

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.